201 HASKINS WAY, SOUTH SAN FRANCISCO, CA
Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer
Reports Business Highlights and Financial Results for the Second Quarter 2026
Shareholder votes
Reports Business Highlights and Financial Results for the First Quarter 2026
Annual Report to Security Holders
Reports Q4 and Full Year 2025 Business and Financial Results
Smital Shah Appointed Chief Financial and Business Officer
Other Events
Q2
FY 2025
Q3
Q1
FY 2024
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Submission Upload
Correspondence